Cointime

Pamlico Biopharma

company

About

Pamlico BioPharma is a research-stage biopharmaceutical company .

  • 1 - 10

Highlights

Total Funding Amount
$2.20M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series A
Last Funding Money Raised
$2.20M
Industries
Biopharma,Biotechnology,Clinical Trials,Health Care
Founded date
Jan 1, 2011
Number Of Employee
1 - 10
Operating Status
Active

Pamlico BioPharma, Inc. develops fully-human monoclonal antibodies (hmAb) for the rapid diagnosis and treatment of infectious diseases and cancer. Pamlico’s lead program is focused on severe pneumonia caused by Streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. Pamlico was founded on technologies from the Oklahoma Medical Research Foundation (OMRF) and from Emory University, and is anticipated to enter clinical trials in late 2015.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$2.20M
Pamlico Biopharma has raised a total of $2.20M in funding over 2 rounds. Their latest funding was raised on Apr 29, 2015 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 29, 2015 Series A $2.20M 1 Accele Venture Partners — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Pamlico Biopharma is funded by 1 investors. Accele Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Accele Venture Partners Yes Series A
Cointime
Содержание
компания